Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2023 14:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
November 03, 2023 15:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special...
October 30, 2023 03:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
October 25, 2023 02:00 ET | Source: Oxurion NV

Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial

Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with...
October 20, 2023 14:01 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
October 20, 2023 14:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
October 11, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio, Kodiak, Ocuphire, Eisai, Apexian, Oculis, Bayer, Novartis, Allegro

New York, USA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio,...
October 10, 2023 14:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
October 10, 2023 01:00 ET | Source: AstriVax

AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag

Dr. Mathieu Peeters brings an extensive clinical vaccine development track record from his senior roles at GSK Vaccines.Barbara Freitag joins AstriVax as an accomplished CFO in the biotech...
October 04, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Diabetic Macular Edema Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies to Watch Out - Novartis, Roche, Kodiak, Oxurion, Ocuphire, Bausch Health, KalVista, Allegro Opthalmics

New York, USA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Diabetic Macular Edema Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies to Watch Out - Novartis, Roche, Kodiak,...